|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Braakhuis BJ, Leemans CR and Visser O:
Incidence and survival trends of head and neck squamous cell
carcinoma in the Netherlands between 1989 and 2011. Oral Oncol.
50:670–675. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Folkman J: Tumor angiogenesis: Therapeutic
implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hsu HW, Wall NR, Hsueh CT, Kim S, Ferris
RL, Chen CS and Mirshahidi S: Combination antiangiogenic therapy
and radiation in head and neck cancers. Oral Oncol. 50:19–26. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vassilakopoulou M, Psyrri A and Argiris A:
Targeting angiogenesis in head and neck cancer. Oral Oncol.
51:409–415. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ferrara N, Gerber HP and LeCouter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Christopoulos A, Ahn SM, Klein JD and Kim
S: Biology of vascular endothelial growth factor and its receptors
in head and neck cancer: Beyond angiogenesis. Head Neck.
33:1220–1229. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nayak S, Goel MM, Chandra S, Bhatia V,
Mehrotra D, Kumar S, Makker A, Rath SK and Agarwal SP: VEGF-A
immunohistochemical and mRNA expression in tissues and its serum
levels in potentially malignant oral lesions and oral squamous cell
carcinomas. Oral Oncol. 48:233–239. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Uehara M, Sano K, Ikeda H, Sekine J, Irie
A, Yokota T, Tobita T, Ohba S and Inokuchi T: Expression of
vascular endothelial growth factor and prognosis of oral squamous
cell carcinoma. Oral Oncol. 40:321–325. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Seki S, Fujiwara M, Matsuura M, Fujita S,
Ikeda H, Asahina I and Ikeda T: Prediction of outcome of patients
with oral squamous cell carcinoma using vascular invasion and the
strongly positive expression of vascular endothelial growth
factors. Oral Oncol. 47:588–593. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhao SF, Yang XD, Lu MX, Sun GW, Wang YX,
Zhang YK, Pu YM and Tang EY: Prognostic significance of VEGF
immunohistochemical expression in oral cancer: A meta-analysis of
the literature. Tumour Biol. 34:3165–3171. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Presta LG, Chen H, O'Connor SJ, Chisholm
V, Meng YG, Krummen L, Winkler M and Ferrara N: Humanization of an
anti-vascular endothelial growth factor monoclonal antibody for the
therapy of solid tumors and other disorders. Cancer Res.
57:4593–4599. 1997.PubMed/NCBI
|
|
13
|
Hurwitz H, Fehrenbacher L, Novotny W,
Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S,
Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and
leucovorin for metastatic colorectal cancer. N Engl J Med.
350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dickler MN, Rugo HS, Eberle CA, Brogi E,
Caravelli JF, Panageas KS, Boyd J, Yeh B, Lake DE, Dang CT, et al:
A phase II trial of erlotinib in combination with bevacizumab in
patients with metastatic breast cancer. Clin Cancer Res.
14:7878–7883. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sandler A, Gray R, Perry MC, Brahmer J,
Schiller JH, Dowlati A, Lilenbaum R and Johnson DH:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fujita K, Sano D, Kimura M, Yamashita Y,
Kawakami M, Ishiguro Y, Nishimura G, Matsuda H and Tsukuda M:
Anti-tumor effects of bevacizumab in combination with paclitaxel on
head and neck squamous cell carcinoma. Oncol Rep. 18:47–51.
2007.PubMed/NCBI
|
|
17
|
Cao S, Durrani FA, Toth K, Rustum YM and
Seshadri M: Bevacizumab enhances the therapeutic efficacy of
Irinotecan against human head and neck squamous cell carcinoma
xenografts. Oral Oncol. 47:459–466. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gyanchandani R, Sano D, Alves Ortega MV,
Klein JD, Knapick BA, Oh S, Myers JN and Kim S: Interleukin-8 as a
modulator of response to bevacizumab in preclinical models of head
and neck squamous cell carcinoma. Oral Oncol. 49:761–770. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang Y, Dong L, Bi Q, Ge X, Zhang X, Wu D,
Fu J, Zhang C, Wang C and Li S: Beyond antiangiogenesis:
Intratumorally injected bevacizumab plays a cisplatin-sensitizing
role in squamous cell carcinomas in mice. Chemotherapy. 57:244–252.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yancik R and Ries LA: Cancer in older
persons: An international issue in an aging world. Semin Oncol.
31:128–136. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Argiris A, Li Y, Murphy BA, Langer CJ and
Forastiere AA: Outcome of elderly patients with recurrent or
metastatic head and neck cancer treated with cisplatin-based
chemotherapy. J Clin Oncol. 22:262–268. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Takahashi T, Ueda S, Kono K and Majima S:
Attempt at local administration of anticancer agents in the form of
fat emulsion. Cancer. 38:1507–1514. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
National Research Council: Guide for the
Care and Use of Laboratory Animals. 8th edition. The National
Academies Press; Washington, DC: 2011, https://grants.nih.gov/grants/olaw/guide-for-the-care-and-use-of-laboratory-animals.pdf
|
|
24
|
Sorace AG, Quarles CC, Whisenant JG,
Hanker AB, McIntyre JO, Sanchez VM and Yankeelov TE: Trastuzumab
improves tumor perfusion and vascular delivery of cytotoxic therapy
in a murine model of HER2+ breast cancer: Preliminary
results. Breast Cancer Res Treat. 155:273–284. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Takeuchi H, Hashimoto N, Kitai R, Kubota T
and Kikuta K: Proliferation of vascular smooth muscle cells in
glioblastoma multiforme. J Neurosurg. 113:218–224. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Patterson DM, Gao D, Trahan DN, Johnson
BA, Ludwig A, Barbieri E, Chen Z, Diaz-Miron J, Vassilev L, Shohet
JM and Kim ES: Effect of MDM2 and vascular endothelial growth
factor inhibition on tumor angiogenesis and metastasis in
neuroblastoma. Angiogenesis. 14:255–266. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mukai M, Kubota S, Morita S and Akanuma A:
A pilot study of combination therapy of radiation and local
administration of OK-432 for esophageal cancer. Five-year survival
and local control rate. Cancer. 75:2276–2280. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tano T, Okamoto M, Kan S, Bando T, Goda H,
Nakashiro K, Shimodaira S, Koido S, Homma S, Fujita T, et al:
Immunochemoradiotherapy for patients with oral squamous cell
carcinoma: Augmentation of OK-432-induced helper T cell 1 response
by 5-FU and X-ray irradiation. Neoplasia. 15:805–814. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yamada T, Hayashi Y, Kaneko R, Tohnai I,
Ueda M and Ito M: Effect of the combination of a local OK-432
injection and hyperthermia on SCC VII tumors in mice. J Radiat Res.
39:101–109. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gibson SL, VanDerMeid KR, Murant RS,
Raubertas RF and Hilf R: Effects of various photoradiation regimens
on the antitumor efficacy of photodynamic therapy for R3230AC
mammary carcinomas. Cancer Res. 50:7236–7241. 1990.PubMed/NCBI
|
|
31
|
Dvorak HF and Gresser I: Microvascular
injury in pathogenesis of interferon-induced necrosis of
subcutaneous tumors in mice. J Natl Cancer Inst. 81:497–502. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Marumo K, Oya M and Murai M: Application
of the interferon minipellet to human renal cell carcinoma in nude
mice. Int J Urol. 4:55–61. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang TD, Choi W, Yoon TH, Lee KJ, Lee JS,
Joo JH, Lee MG, Yim HS, Choi KM, Kim B, et al: In vivo photothermal
treatment by the peritumoral injection of macrophages loaded with
goldnanoshells. Biomed Opt Express. 7:185–193. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kitamura K, Takahashi T, Kotani T,
Miyagaki T, Yamaoka N, Tsurumi H, Noguchi A and Yamaguchi T: Local
administration of monoclonal antibody-drug conjugate: A new
strategy to reduce the local recurrence of colorectal cancer.
Cancer Res. 52:6323–6328. 1992.PubMed/NCBI
|
|
35
|
Kliche S and Waltenberger J: VEGF receptor
signaling and endothelial function. IUBMB Life. 52:61–66. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yazama H, Kitatani K, Fujiwara K, Kato M,
Hashimoto-Nishimura M, Kawamoto K, Hasegawa K, Kitano H, Bielawska
A, Bielawski J and Okazaki T: Dietary glucosylceramides suppress
tumor growth in a mouse xenograft model of head and neck squamous
cell carcinoma by the inhibition of angiogenesis through an
increase in ceramide. Int J Clin Oncol. 20:438–446. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Henriques AC, de Matos FR, Galvão HC and
Freitas Rde A: Immunohistochemical expression of MMP-9 and VEGF in
squamous cell carcinoma of the tongue. J Oral Sci. 54:105–111.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Aggarwal S, Devaraja K, Sharma SC and Das
SN: Expression of vascular endothelial growth factor (VEGF) in
patients with oral squamous cell carcinoma and its clinical
significance. Clin Chim Acta. 436:35–40. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Folkman J: Role of angiogenesis in tumor
growth and metastasis. Semin Oncol. 29 Suppl 16:S15–S18. 2002.
View Article : Google Scholar
|
